Juno Therapeutics Inc (JUNO.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||Independent Chairman of the Board|
|52||2013||President, Chief Executive Officer, Director|
|47||2017||President of Research & Development|
|46||2014||Chief Financial Officer, Head of Corporate Development|
|54||2015||Executive vice president - Research, chief scientific officer|
- BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
- BRIEF-Juno Therapeutics reports Q3 adjusted loss per share $0.73
- BRIEF-Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform
- BRIEF-Juno Therapeutics prices $250 million follow-on offering
- BRIEF-Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing